Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 11/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14468581 | 0.85 | PRKDC (0.38) | PRKDCP2RY12NPC1RAB9A | |
| SCHEMBL14447676 | 0.83 | PRKDC (0.37) | PRKDCNPC1RAB9A | |
| SCHEMBL5454450 | 0.81 | PRKDC (0.48) | PRKDCPOLBKITFLT3 | |
| SCHEMBL5451022 | 0.81 | PRKDC (0.37) | PRKDCATMP2RY12POLBMAPK8 | |
| SCHEMBL5448683 | 0.79 | PRKDC (0.49) | PRKDCATMP2RY12PIK3CG | |
| SCHEMBL5801741 | 0.78 | KIF11 (0.44) | PRKDCATMPIK3CGMEN1KMT2A | |
| SCHEMBL5440522 | 0.76 | PRKDC (0.48) | PRKDCPOLBKITFLT3 | |
| SCHEMBL14802146 | 0.75 | PRKDC (0.47) | PRKDCPOLB | |
| SCHEMBL5453418 | 0.73 | PRKDC (0.52) | PRKDCPIK3CGPOLB | |
| SCHEMBL14802147 | 0.72 | PRKDC (0.40) | PRKDCP2RY12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404681-B2 | Xanthones, thioxanthones and acridinones as DNA-PK inhibitors | LUITPOLD PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | LUITPOLD PHARMACEUTICALS, INC. | 2007-07-19 | — | — | US | disclosed |
| EP-1660473-A2 | XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS | Luitpold Pharmaceuticals, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2004085418-A2 | XANTHONES, THIOXANTHONES AND ACRIDINONES AS DNA-PK INHIBITORS | LUITPOLD PHARMACEUTICALS, INC. (US) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167441-A1 | Xanthones, thioxanthones and acridinones as dna-pk inhibitors | DCK, DTYMK, XPA | PRKDC 12/4885ATM 4/4885P2RY12 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.